A detailed history of Geneos Wealth Management Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Geneos Wealth Management Inc. holds 9,039 shares of LLY stock, worth $7.19 Million. This represents 0.31% of its overall portfolio holdings.

Number of Shares
9,039
Previous 9,078 0.43%
Holding current value
$7.19 Million
Previous $8.22 Million 2.57%
% of portfolio
0.31%
Previous 0.37%

Shares

35 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$772.14 - $960.02 $30,113 - $37,440
-39 Reduced 0.43%
9,039 $8.01 Million
Q2 2024

Jul 23, 2024

SELL
$724.87 - $909.04 $519,006 - $650,872
-716 Reduced 7.31%
9,078 $8.22 Million
Q1 2024

May 03, 2024

BUY
$592.2 - $792.28 $333,408 - $446,053
563 Added 6.1%
9,794 $7.62 Million
Q4 2023

Jan 26, 2024

SELL
$525.19 - $619.13 $340,323 - $401,196
-648 Reduced 6.56%
9,231 $5.38 Million
Q3 2023

Oct 11, 2023

BUY
$434.7 - $599.3 $38,688 - $53,337
89 Added 0.91%
9,879 $5.31 Million
Q2 2023

Aug 08, 2023

BUY
$350.74 - $468.98 $575,915 - $770,065
1,642 Added 20.15%
9,790 $4.59 Million
Q1 2023

Apr 25, 2023

SELL
$310.63 - $364.82 $254,095 - $298,422
-818 Reduced 9.12%
8,148 $2.8 Million
Q4 2022

Jan 30, 2023

SELL
$321.55 - $374.67 $137,301 - $159,984
-427 Reduced 4.55%
8,966 $3.28 Million
Q3 2022

Nov 14, 2022

SELL
$296.48 - $337.87 $1.24 Million - $1.41 Million
-4,177 Reduced 30.78%
9,393 $3.04 Million
Q2 2022

Jul 22, 2022

SELL
$278.73 - $327.27 $86,963 - $102,108
-312 Reduced 2.25%
13,570 $4.4 Million
Q1 2022

May 16, 2022

SELL
$234.69 - $291.66 $237,740 - $295,451
-1,013 Reduced 6.8%
13,882 $3.98 Million
Q4 2021

Feb 09, 2022

SELL
$224.85 - $279.04 $288,257 - $357,729
-1,282 Reduced 7.92%
14,895 $4.11 Million
Q3 2021

Nov 09, 2021

SELL
$221.6 - $272.71 $24,819 - $30,543
-112 Reduced 0.69%
16,177 $3.71 Million
Q2 2021

Jul 08, 2021

BUY
$180.55 - $233.54 $499,040 - $645,504
2,764 Added 20.44%
16,289 $3.81 Million
Q1 2021

Jun 17, 2021

BUY
$164.32 - $212.72 $40,422 - $52,329
246 Added 1.85%
13,525 $2.47 Million
Q4 2020

May 19, 2021

SELL
$130.46 - $172.63 $32,484 - $42,984
-249 Reduced 1.84%
13,279 $2.37 Million
Q3 2020

Sep 07, 2021

SELL
$146.22 - $169.13 $80,421 - $93,021
-550 Reduced 3.91%
13,528 $2.03 Million
Q2 2020

Sep 07, 2021

SELL
$136.42 - $164.18 $14,460 - $17,403
-106 Reduced 0.75%
14,078 $2.29 Million
Q1 2020

Sep 07, 2021

BUY
$119.05 - $147.35 $23,690 - $29,322
199 Added 1.42%
14,184 $1.9 Million
Q4 2019

Sep 07, 2021

BUY
$106.92 - $132.43 $19,245 - $23,837
180 Added 1.3%
13,985 $1.84 Million
Q3 2019

Sep 07, 2021

SELL
$106.79 - $116.16 $1,067 - $1,161
-10 Reduced 0.07%
13,805 $1.55 Million
Q2 2019

Sep 07, 2021

BUY
$110.79 - $129.32 $47,528 - $55,478
429 Added 3.2%
13,815 $1.53 Million
Q1 2019

Sep 07, 2021

SELL
$111.31 - $131.02 $13,245 - $15,591
-119 Reduced 0.88%
13,386 $1.74 Million
Q4 2018

Sep 07, 2021

SELL
$105.9 - $118.64 $44,372 - $49,710
-419 Reduced 3.01%
13,505 $1.54 Million
Q3 2018

Sep 07, 2021

BUY
$85.86 - $107.31 $104,148 - $130,167
1,213 Added 9.54%
13,924 $1.49 Million
Q2 2018

Sep 07, 2021

SELL
$75.7 - $86.88 $31,794 - $36,489
-420 Reduced 3.2%
12,711 $1.08 Million
Q1 2018

Sep 07, 2021

SELL
$74.21 - $87.6 $26,196 - $30,922
-353 Reduced 2.62%
13,131 $1.02 Million
Q4 2017

Sep 07, 2021

SELL
$81.94 - $87.89 $103,572 - $111,092
-1,264 Reduced 8.57%
13,484 $1.14 Million
Q3 2017

Sep 07, 2021

BUY
$77.07 - $85.54 $19,575 - $21,727
254 Added 1.75%
14,748 $1.26 Million
Q2 2017

Sep 07, 2021

BUY
N/A
40 Added 0.28%
14,494 $1.19 Million
Q1 2017

Sep 07, 2021

SELL
N/A
-108 Reduced 0.74%
14,454 $1.22 Million
Q4 2016

Sep 07, 2021

BUY
N/A
650 Added 4.67%
14,562 $1.07 Million
Q3 2016

Sep 07, 2021

BUY
N/A
850 Added 6.51%
13,912 $1.12 Million
Q2 2016

Sep 07, 2021

BUY
N/A
214 Added 1.67%
13,062 $1.03 Million
Q1 2016

Sep 07, 2021

BUY
N/A
12,848
12,848 $943,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $756B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Geneos Wealth Management Inc. Portfolio

Follow Geneos Wealth Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geneos Wealth Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Geneos Wealth Management Inc. with notifications on news.